Can Semaglutide and Tirzepatide Be Combined? What the Evidence Shows

The direct answer

What a semaglutide + tirzepatide combination is

A compounded semaglutide + tirzepatide combination would be a preparation made by a licensed compounding pharmacy that contains both active pharmaceutical ingredients in a single dose. To understand why this is a significant step, it helps to see what each drug is on its own.

Semaglutide

A GLP-1 receptor agonist — it activates a single receptor (GLP-1) to reduce appetite and slow gastric emptying.

Tirzepatide

A dual GIP/GLP-1 receptor agonist — it activates both GIP and GLP-1 receptors.

A combination

Would combine a GLP-1 agonist with a dual GIP/GLP-1 agonist — meaning the GLP-1 receptor would be activated twice over.

Tirzepatide already includes GLP-1 agonism as part of its dual mechanism, so a combination with semaglutide activates the GLP-1 receptor through both ingredients.

Why unique compounded formulations exist

Compounding pharmacies prepare medications on a prescription-by-prescription basis, and that flexibility means they can combine active ingredients, adjust doses, or change the route of administration in ways that FDA-approved products do not. This is why the market includes formulations — such as combinations of semaglutide and tirzepatide, or versions mixed with other substances — that do not exist as approved products.

A 2026 study that characterized marketed compounded GLP-1 products identified dozens of unique semaglutide and tirzepatide preparations, illustrating how varied — and how far from a single standardized product — this category can be (Belcourt et al., 2026).

Compounded medications are not FDA-approved, and the FDA has documented concerns about unapproved GLP-1 drugs. A 2026 Stanford report described a case where tirzepatide compounded with vitamin B12 chemically bonded into a new molecule, an example of how adding ingredients to a compounded preparation can create an uncharacterized product.

Each drug, and the combination

Here is how each medication is used on its own, and how a compounded combination fits in.

Each drug alone

Semaglutide and tirzepatide each have large, randomized, placebo-controlled trials supporting their separate use (the STEP program for semaglutide; the SURMOUNT program for tirzepatide). A head-to-head trial (SURPASS-2) compared the two in type 2 diabetes. In obesity, the head-to-head comparison is SURMOUNT-5 — see the SURMOUNT-5 clinical trial results.

The combination

A compounded semaglutide + tirzepatide combination is not FDA-approved. It is prepared by a licensed compounding pharmacy for individual patients when a licensed provider determines it is medically appropriate.

The distinction matters: adding a second GLP-1 agent overlaps on the same pathway, so a licensed provider evaluates whether the combination is appropriate for your individual health profile before recommending it.

Oral formulation considerations

The "oral" part of an oral semaglutide + tirzepatide combination adds another layer of uncertainty. Understanding the approved landscape is important:

• Oral semaglutide is FDA-approved as Wegovy tablets (weight management in eligible adults) and as Rybelsus (type 2 diabetes).
• There is no FDA-approved oral tirzepatide. The remaining FDA-approved semaglutide and tirzepatide products — Wegovy injection, Zepbound, Ozempic, and Mounjaro — are injectables.
• Surfbound's compounded oral formulations are not FDA-approved. Its compounded oral semaglutide + tirzepatide combination, compounded oral semaglutide, and compounded oral tirzepatide are distinct compounded products — the combination has no approved reference product.

Oral administration is not simply an injectable drug in a tablet. Peptide medications can be affected by stomach acid and absorption differences, which is why an oral form is formulated specifically for delivery by mouth rather than adapted from an injectable.

Safety and regulatory status

Compounded medications are not FDA-approved. They are prepared by licensed compounding pharmacies for individual patients, and this applies to any compounded semaglutide + tirzepatide combination.

• The FDA has issued a public statement documenting its concerns with unapproved GLP-1 drugs, including compounded semaglutide and tirzepatide products (June 15, 2026).
• A 2026 report described tirzepatide compounded with vitamin B12 forming a new, unstudied molecule — an example of how combining ingredients in compounding can create an uncharacterized product.

Compounded medications are prepared by licensed pharmacies for individual patients and are not FDA-approved.

Surfbound's provider-reviewed option

Surfbound Health offers a compounded semaglutide + tirzepatide combination oral, plus each medication as a separate, single-agent option, prescribed only after an independent licensed provider reviews your health history and determines whether treatment is medically appropriate.

• Compounded injectable semaglutide — $169/mo, all doses.
• Compounded injectable tirzepatide — $219/mo, all doses.
• Compounded oral semaglutide and oral tirzepatide are also offered as separate daily-tablet options, plus a compounded combination oral.

Compounded medications are not FDA-approved. Treatment requires a licensed provider review, prescriptions are never automatic, and not everyone qualifies.

References

1. 1.Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). The New England Journal of Medicine, 2021. New England Journal of Medicine · 2021
2. 2.U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration · June 15, 2026
3. 3.Stanford Medicine. Compounded GLP-1s: Why doctors worry and the FDA is concerned. Stanford Medicine · July 16, 2026
4. 4.Belcourt J, et al. Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown. PubMed (PMID 41689811) · 2026
5. 5.Novo Nordisk. Rybelsus (semaglutide) prescribing information — oral semaglutide approved for type 2 diabetes, not chronic weight management. Novo Nordisk / FDA labeling · 2026
6. 6.Eli Lilly and Company. Zepbound (tirzepatide) prescribing information — injectable only; no FDA-approved oral tirzepatide formulation exists. Eli Lilly and Company / FDA labeling · 2026
7. 7.U.S. Food and Drug Administration. Wegovy (semaglutide) prescribing information — FDA-approved oral semaglutide (Wegovy tablets) for chronic weight management in eligible adults. FDA labeling (Wegovy prescribing information) · 2026

Content is provided for general health information only and does not constitute medical advice. A licensed provider determines whether any treatment is medically appropriate for you. Compounded medications are not FDA-approved.